Daewon Pharmaceutical Co., Ltd. (KRX:003220)
13,200
-60 (-0.45%)
Last updated: Jun 27, 2025
Daewon Pharmaceutical Revenue
Daewon Pharmaceutical had revenue of 157.83B KRW in the quarter ending March 31, 2025, a decrease of -0.30%. This brings the company's revenue in the last twelve months to 597.69B, up 6.51% year-over-year. In the year 2024, Daewon Pharmaceutical had annual revenue of 598.16B with 13.51% growth.
Revenue (ttm)
597.69B
Revenue Growth
+6.51%
P/S Ratio
0.47
Revenue / Employee
465.86M
Employees
1,283
Market Cap
283.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 598.16B | 71.21B | 13.51% |
Dec 31, 2023 | 526.95B | 48.07B | 10.04% |
Dec 31, 2022 | 478.88B | 124.71B | 35.21% |
Dec 31, 2021 | 354.18B | 45.68B | 14.81% |
Dec 31, 2020 | 308.50B | -9.33B | -2.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
SK Biopharmaceuticals | 578.00B |
HLB Co., Ltd. | 74.64B |
PharmaResearch | 392.31B |
Peptron | 4.30B |